Morgan Stanley assumed coverage of Tempus AI (TEM) with an Overweight rating and a price target of $85, up from $80. Life Science Tools and Diagnostics end market bright spots are beginning to emerge and the firm sees “plenty of catalysts” in the pipeline across its coverage, adding that it sees “lots to like in the space entering 2026.” However, a recent industry valuation spike in the second half of the year leaves multiples in “a fair place,” so the firm starts the group with an In-Line industry view, the analyst tells investors. Among the group, the analyst identifies Danaher (DHR) as Top Pick.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI price target raised to $105 from $96 at BTIG
- Cathie Wood Sells Tesla (TSLA) and SoFi Stocks, Makes a $34M Bet on This USDC Giant
- Tempus AI management to meet virtually with BTIG
- Tempus AI price target raised to $80 from $68 at Morgan Stanley
- Tempus AI price target lowered to $80 from $105 at Piper Sandler